ArticleGene therapy2000
Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins.
Article in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 156 citations in OpenAlex.
- Gene Therapy for Heart Failure.Journal of cardiovascular translational research · 2026Review
- AAV delivery strategy with mechanical support for safe and efficacious cardiac gene transfer in swine.Nature communications · 2024Article
- Review
- Gene therapy for atrial fibrillation.Journal of molecular and cellular cardiology · 2024Review
- Caridac vein retroinjections provide an efficient approach for global left ventricular gene transfer with adenovirus and adeno-associated virus.Scientific reports · 2024Article
- Small non-coding RNA therapeutics for cardiovascular disease.European heart journal · 2022Review
- Recent advances in gene therapy for atrial fibrillation.Journal of cardiovascular electrophysiology · 2021Review
- Primary Soft Tissue Sarcoma of the Heart: An Emerging Chapter in Cardio-Oncology.Biomedicines · 2021Review
- Novel molecular targets for coronary angiogenesis and ischemic heart disease.Coronary artery disease · 2017Review
- Cardiac gene therapy with adeno-associated virus-based vectors.Current opinion in cardiology · 2017Article
- Cardiac gene therapy: are we there yet?Gene therapy · 2016Review
- Gene therapy for the treatment of heart failure: promise postponed.European heart journal · 2016Review
- The Use of Gene Therapy for Ablation of Atrial Fibrillation.Arrhythmia & electrophysiology review · 2014Article
- A needleless liquid jet injection delivery method for cardiac gene therapy: a comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression.Journal of cardiovascular translational research · 2014Article
- Surgical methods for cardiac gene transfer.Future cardiology · 2014Review
- The road ahead: working towards effective clinical translation of myocardial gene therapies.Therapeutic delivery · 2014Review
- Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications.Human gene therapy · 2013Review
- Heart failure gene therapy: the path to clinical practice.Circulation research · 2013Review
- Percutaneous approaches for efficient cardiac gene delivery.Journal of cardiovascular translational research · 2013Review
- Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability.Human gene therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catheter-based percutaneous transluminal gene delivery (PTGD) into the coronary artery still falls behind the expectations of an efficient myocardial gene delivery system. In this study gene delivery was applied by selective pressure-regulated retroinfusion through the coronary veins to prolong adhesion of replication defective adenovirus within the targeted myocardium. Adenoviral vectors consisted either of luciferase (Ad.rsv-Luc) or beta-galactosidase (Ad.rsv-betaGal) reporter gene under control of an unspecific promotor derived from the Rous sarcoma virus (RSV). In this pig model, selective retrograde gene delivery into the anterior cardiac vein during a brief period of ischemia substantially increased reporter gene expression in the targeted myocardium (LAD region) compared with antegrade delivery as a control. Repeated retrograde delivery during two periods of brief ischemia resulted in a more homogeneous transmural expression predominantly observed in cardiomyocytes (X-gal-staining). In the nontargeted myocardium (CX region) there was no evidence for adenoviral transfection. From our data we infer that selective pressure-regulated retroinfusion is a promising approach for efficient percutaneous transluminal gene delivery to the myocardium. Gene Therapy (2000) 7, 232-240.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.